Korea's Green Cross Sees Earnings Plunge As Flu Fears Wane
This article was originally published in PharmAsia News
SEOUL - As widely expected, vaccine producer Green Cross, one of Korea's leading pharmas, has seen a sharp drop in its sales and net profit during the fourth quarter of last year
You may also be interested in...
Following its entry into North America and China, Green Cross is set to make inroads into the rapidly growing Russian pharmaceutical market through a strategic partnership with Nanolek to commercialize the South Korean biopharmaceutical company’s biologics.
Hanmi Pharmaceutical inks another deal with a foreign pharma company as it focuses on business opportunities outside Korea.
Korea's Green Cross Files For Biobetter Of Shire's Hunter Syndrome Therapy Elaprase; Seeks Global Partners
SEOUL - South Korea's leading vaccine manufacturer Green Cross Corp. took a step forward in the biosimilars sector by submitting a marketing application to Korea FDA for a biobetter of Shire PLC's Elaprase (idursulfase) for Hunter syndrome. And now the company is looking for foreign partners